CXCL8 and non-small cell lung carcinoma: A large retrospective analysis of 1344 patients with melanoma, NSCLC or renal cell carcinoma showed that high baseline serum IL-8 (≥23 pg/mL) was associated with poorer OS and clinical outcomes in response to nivolumab and/or ipilimumab, everolimus or docetaxel treatment [150].